



Jacquie Chirgwin

Contact

Jacquie Chirgwin

Publications (5)

Colleoni M, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribí K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber R, Coates A, Di Leo A, Regan M, Goldhirsch A, O'Reilly S, Müller B, Marth C, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas M, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2017; 19:127-138.

Colleoni M, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber R, Regan M, Coates A, Price K, Viale G, Kralidis E, Tondini C, Gray K, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E, Gomez H, Linderholm B, Puglisi F, Goldhirsch A. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. *J Clin Oncol* 2016

Chirgwin J, Coates A, Goldhirsch A, Regan M, Bonnefoi H, Ejlertsen B, Thürlimann B, Price K, Smith I, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. *Breast Cancer Res Treat* 2011; 131:295-306.

Colleoni M, Coates A, Gelber R, Price K, Wardley A, Pienkowski T, Chirgwin J, Smith I, Láng I, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Regan M, Giobbie-Hurder A, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. *J Clin Oncol* 2011; 29:1117-24.

Coates A, Del Mastro L, Smith I, Chirgwin J, Nogaret J, Pienkowski T, Wardley A, Jakobsen E, Price K, Láng I, Colleoni M, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. *JCO* 2007; 25:486-92.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch